TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...

Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.

Tenecteplase is administered as a single, 5-second intravenous bolus, providing a faster and simpler option compared to the ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug ...

Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...

Notably, off-label tenecteplase had already become the preferred thrombolytic for acute ischemic stroke before the expanded ...

Genentech announced that the U.S. Food and Drug Administration has approved TNKase, a thrombolytic or clot-dissolving agent, for the treatment ...

The approval was supported by data from the registry-linked, parallel group, open-label, randomized AcT trial, which compared tenecteplase to alteplase.

The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the ...

"TNKase provides a faster and simpler administration, which can be critical for anyone who is dealing with an acute stroke." Approval of TNKase was granted to Genentech.